Catalyst OrthoScience is introducing the Archer™ R1 Reverse Shoulder as its Archer™ CSR Total Shoulder System continues to gain market share. Limited launch commences within 2Q21, with commercial launch slated to occur later this year.
Catalyst announced FDA 510(k) clearance of the Archer R1 Reverse Shoulder in 1Q21, expanding its portfolio with multiple arthroplasty options. Catalyst’s reverse shoulder system is a single-tray arthroplasty system engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. It offers surgeon-targeted implant positioning and bone sparing implants.
As part of this milestone, the company is rebranding its flagship stemless, ellipsoid anatomic system, introduced in 2016, to the Archer CSR Total Shoulder System. The Archer CSR is a single-tray, bone-preserving total shoulder system containing a precision elliptical humeral head and less invasive glenoid component.
Brian K. Hutchison, chairman and CEO, said, “The tenets of our product portfolio are centered around precise, targeted placement of bone-sparing implants. Our next generation implant design, paired with unique, patented instrumentation and streamlined surgical techniques, allows for surgeon-targeted implant positioning.”